EN DE
Watch ArriVent BioPharma, Inc. Common Stock for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ArriVent BioPharma, Inc. (AVBP) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of ArriVent BioPharma, Inc. stock $8.66, price $13.51, that is 35.9% below the price, quality 35 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US04272N1028

AB ArriVent BioPharma, Inc. logo Thin data Nov 12, 2026

ArriVent BioPharma, Inc.

AVBP · US
Very expensive, weak quality

Our calculation puts a fair price 36% below what the stock costs today.

Fair value $8.66 · Strongly overvalued
Quality 35/100
Negative free cash flow
Trails peers (2/6)
Narrow moat 8/100 · thin data
Thin data
Estimate
Watch ArriVent BioPharma, Inc. Common Stock for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$35.63 $12.23 Fair Value $8.66 Jan 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.

How to read this chart

34‑month range $12.23 – $35.63 · fair‑value band $6.49 – $10.82 · the $13.51 price screens above the $8.66 fair value. As of Nov 12, 2026.

Follow ArriVent BioPharma, Inc. Common Stock in your weekly email

Every Wednesday you see whether ArriVent BioPharma, Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.

Show moreShow less

The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.

It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors.

The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Stock analysis

ArriVent BioPharma, Inc. (AVBP) currently trades at $13.51, while our estimate is $8.66, 36% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $6.49 (bear) to $10.82 (bull), the price of $13.51 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

ArriVent BioPharma, Inc. Common Stock reported revenue of $0 in FY2025 versus $0 in FY2022. Reported net income was −$166M in FY2025.

Key figures

Market cap $643M Small · EPS (TTM) $−3.62 · Return on equity −48.7% · Return on assets (EBIT) −34.7% (5-year average) · Operating margin −868% · Revenue (TTM) $5.0M · Free cash flow −$161M · Net cash $45.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 61% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −36%, AVBP screens richer than that median.

Fair Value

Bear $6.49 Fair Value $8.66 Bull $10.82
Price $13.51 · Downside -35.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 66
Do the profits arrive as real cash?
Financial strength 86
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 5
How calm the share price moves, does not count
Price momentum 7
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 4
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • SaleHHLR ADVISORS, LTD.10% owner555,555 shares at $23.37$13.0MDec 10, 2025

Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

AVBP screens overvalued: fair value 36% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare ArriVent BioPharma, Inc. Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 35 · Below median
Fair Value upside −35.9% · Below median
Profitability
Return on assets −49.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.09× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $959.41 $1,275 +33% vs AVBP
Vertex Pharmaceuticals Incorporated VRTX $547.03 $602.68 +10% vs AVBP
Samsung Biologics Co 207940 1,430,000 KRW 1,573,000 KRW +10% vs AVBP
Genmab A/S GMAB kr 3,561 kr 3,880 +9% vs AVBP
argenx SE ARGX $977.58 $908.40 −7% vs AVBP
CSL Limited CSL A$204.54 A$181.40 −11% vs AVBP
Moderna, Inc MRNA $248.69 $158.70 −36% vs AVBP
BeOne Medicines AG 6160 HK$251.80 HK$152.80 −39% vs AVBP
Celltrion, Inc 068270 207,000 KRW 74,945 KRW −64% vs AVBP
Royalty Pharma plc RPRX $70.01 $19.01 −73% vs AVBP

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ArriVent BioPharma, Inc. Common Stock: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ArriVent BioPharma, Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/AVBP

Frequently asked questions

Is ArriVent BioPharma, Inc. (AVBP) overvalued or undervalued?
As of Nov 12, 2026, our estimate of fair value is $8.66 versus a price of $13.51, about 36% lower (overvalued).
What is the fair value of AVBP?
Our estimate for ArriVent BioPharma, Inc. is $8.66 (as of Nov 12, 2026), built from audited fundamentals. The current price: $13.51.
What is the quality score of AVBP?
ArriVent BioPharma, Inc. has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ArriVent BioPharma, Inc. (AVBP)?
Our calculated price target is the estimate of $8.66 (as of Nov 12, 2026). Cautious scenario $6.49, optimistic scenario $10.82. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the ArriVent BioPharma, Inc. Common Stock stock forecast for 2026?
Our estimate puts fair value at $8.66, about 36% lower versus a price of $13.51 (overvalued). Cautious scenario $6.49, optimistic scenario $10.82. The calculation is refreshed regularly with new filings.
What is the revenue of ArriVent BioPharma, Inc. (AVBP)?
ArriVent BioPharma, Inc. reported trailing-twelve-month revenue of about $5.0M (latest available figure, as of Nov 12, 2026).
What is the intrinsic value of ArriVent BioPharma, Inc. (AVBP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ArriVent BioPharma, Inc. it is $8.66 per share (as of Nov 12, 2026), against a price of $13.51.
Is ArriVent BioPharma, Inc. Common Stock stock overvalued or undervalued in 2026?
As of Nov 12, 2026, AVBP trades above its calculated fair value: price $13.51, fair value $8.66, a gap of about −36% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AVBP?
No. The price is what the market pays today ($13.51); the fair value is what the company's own numbers justify ($8.66). For ArriVent BioPharma, Inc. the two are $4.85 per share apart. That gap is exactly why we show both numbers side by side.
How much is ArriVent BioPharma, Inc. Common Stock worth?
The market values ArriVent BioPharma, Inc. at about $643M (market capitalisation, as of Nov 12, 2026). Per share that is $13.51; our models calculate a fair value of $8.66 per share.
What do the bullish and bearish scenarios say about AVBP?
Our models span a range for ArriVent BioPharma, Inc.: cautious scenario $6.49, base $8.66, optimistic $10.82 per share (as of Nov 12, 2026, price $13.51). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ArriVent BioPharma, Inc. (AVBP)?
Balance-sheet figures for ArriVent BioPharma, Inc. (as of Nov 12, 2026): return on equity −48.7%. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is AVBP from its 52-week high?
ArriVent BioPharma, Inc. trades at $13.51, about 61% below its 52-week high of $34.74 and 10% above the low of $12.23 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of $8.66 is for.
Which stocks are comparable to ArriVent BioPharma, Inc. Common Stock?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ArriVent BioPharma, Inc. Common Stock stock attractive at the current price?
The data as of Nov 12, 2026: price $13.51, calculated fair value $8.66 (−36%), Quality Score 35/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. ArriVent BioPharma, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ArriVent BioPharma, Inc. (AVBP)?
The closing price on Nov 11, 2026 was $13.51. Our estimate is $8.66, about 36% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ArriVent BioPharma, Inc. Common Stock right now?
The price sits above even our optimistic bull case ($10.82). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of ArriVent BioPharma, Inc.

How large is the market capitalisation of ArriVent BioPharma, Inc. (AVBP)?
The market capitalisation of ArriVent BioPharma, Inc. is $643M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of ArriVent BioPharma, Inc. (AVBP)?
Earnings per share at ArriVent BioPharma, Inc. are $−3.62. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of ArriVent BioPharma, Inc. (AVBP)?
The return on equity (ROE) of ArriVent BioPharma, Inc. is −48.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ArriVent BioPharma, Inc. (AVBP)?
On an EBIT basis the return on assets of ArriVent BioPharma, Inc. is −34.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ArriVent BioPharma, Inc. (AVBP)?
The operating margin of ArriVent BioPharma, Inc. is −868% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does ArriVent BioPharma, Inc. (AVBP) generate?
The free cash flow of ArriVent BioPharma, Inc. is −$161M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does ArriVent BioPharma, Inc. (AVBP) hold?
ArriVent BioPharma, Inc. holds more cash than debt, $45.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch ArriVent BioPharma, Inc. Common Stock in the live analysis

One click puts ArriVent BioPharma, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.